Back to results
US 7,794,731 B2Granted
Use of flagellin in the immunotherapy of Yersinia pestis
AssigneeWake Forest University Health Sciences
InventorsSteven B. Mizel, Anna Nichole Honko
Life of this patent
Estimating the term…
Abstract
The invention provides a fusion protein comprising a flagellin adjuvant and a Yersinia pestis antigen. Also provided are compositions comprising a flagellin adjuvant and a Yersinia pestis antigen. The invention also discloses methods of making a fusion protein comprising a flagellin adjuvant and a Yersinia pestis antigen. The invention further provides pharmaceutical formulations and methods for inducing an immune response against Yersinia pestis.
Claims21
An isolated fusion protein comprising:
- (a) an isolated flagellin adjuvant comprising:
- (i) a flagellin N-terminal constant region;
- and
- (ii) a flagellin C-terminal constant region;
- and
- (b) a Yersinia pestis antigen between the flagellin N-terminal constant region and the flagellin C-terminal constant region, wherein the Y. pestis antigen comprises Y. pestis F1 antigen, Y. pestis V antigen, or a fusion peptide of Y. pestis F1 antigen and Y. pestis V. antigen;
- and
- wherein the flagellin N-terminal constant region and/or the flagellin C-terminal constant region of the isolated flagellin adjuvant comprises a TLR5 recognition site and is able to activate the TLR5 pathway.
5 more elements
An isolated fusion protein comprising:
- (a) a flagellin adjuvant comprising:
- (i) a flagellin N-terminal constant region;
- and
- (ii) a flagellin C-terminal constant region;
- and
- (b) a Yersinia pestis antigen, wherein the antigen is a fusion peptide of Y. pestis F1 antigen and Y. pestis V antigen and is inserted within the flagellin hypervariable region between the flagellin N-terminal constant region and the flagellin C-terminal constant region.
3 more elements
Dependencies are inferred from the claim text.